News Releases

Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.

Month Year

Oct 12, 2021

Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) with Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
Sep 28, 2021

Astellas Recognized Consistently Among Top Companies for Working Parents

Astellas ranked again in Seramount's 100 Best Companies and Best Companies for Dads lists.
Sep 27, 2021

Japan's MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer

- Enfortumab vedotin is the first and only antibody-drug conjugate (ADC) approved in Japan for patients with advanced urothelial cancer -
Sep 22, 2021

Astellas to Present Fezolinetant 12-Week Findings from Phase 3 SKYLIGHT 2™ Trial in Oral Session at The North American Menopause Society 2021 Annual Meeting

Astellas' investigational non-hormonal treatment demonstrates reduction in frequency and severity of moderate to severe vasomotor symptoms (VMS) associated with menopause
Sep 21, 2021

Astellas and MBC BioLabs Announce Future Innovator Prize to Help Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts

Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise for scientific innovators
Sep 17, 2021

Astellas' and Pfizer's XTANDI® (enzalutamide) Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES Study

Late-breaking abstract to be presented September 18 during European Society for Medical Oncology Congress 2021
- Photos 1
Sep 14, 2021

Astellas Reports Update to September 1 Announcement on the ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy
Sep 1, 2021

Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy
Aug 19, 2021

Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

Roxadustat is the first orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor available for adult patients with anemia associated with chronic kidney disease in Europe
Aug 18, 2021

Astellas Partners with LabCentral to Help Emerging Biotechs Accelerate Preclinical Scientific Research

Astellas' "Future Innovator Prize" sponsorship provides access to life-science incubator and in-house Astellas expertise for scientific entrepreneurs with cutting-edge ideas

Show per page

Statements

Careers

Stay Connected

Get only the email alerts you want.

Media Contacts

For media inquiries and reporter requests, please click here to fill out a request form.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.

Download Fact Sheet

Sustainability

Investors

Explore U.S. Products

News Releases

You are now leaving XTANDI.com

You are now leaving newsroom.astellas.com.